16 completed. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 16 |
| Phase 2 | 1 | Completed 1 |
Follow Hyperkalemia: new trials by email Literature Review of Hyperkalemia trials Research Report on Hyperkalemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) - Hyperkalemia, Renal Insufficiency, Chronic | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 262 | 2022-02-10 | 2026-04-13 |
| Lokelma for RAAS Maximisation in CKD & Heart Failure. Lokelma Oral Product - Chronic Kidney Diseases, Heart Failure With Reduced Ejection Fraction | Phase 3 | Completed | St George's, University of London | 112 | 2022-01-19 | 2026-04-27 |
| A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia Calcium, hydrolysed divinylbenzene-Me 2-fluoro-2-propenoate-1, 7-octadiene polymer sorbitol complexes, Placebo - Hyperkalemia | Phase 3 | Completed | Zeria Pharmaceutical | 85 | 2021-08-03 | 2023-04-20 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. Sodium Zirconium Cyclosilicate 5g, Sodium Zirconium Cyclosilicate 10g, Placebo - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 270 | 2021-05-06 | 2025-05-14 |
| Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects Sodium Zirconium Cyclosilicate, Placebo - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 134 | 2020-11-16 | 2023-03-28 |
| Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) Patiromer, Placebos - Hyperkalemia | Phase 3 | Completed | Vifor Pharma, Inc. | 1195 | 2019-04-24 | 2023-02-24 |
| A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. Placebo, Sodium Zirconium Cyclosilicate (ZS) - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 196 | 2017-12-14 | 2020-02-20 |
| Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia Zirconium Cyclosilicate - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 150 | 2017-09-04 | 2020-05-01 |
| ZS Ph2/3 Dose-response Study in Japan Sodium Zirconium Cyclosilicate (ZS) 5g, Sodium Zirconium Cyclosilicate (ZS) 10g, Placebo - Hyperkalemia | Phase 2 / Phase 3 | Completed | AstraZeneca | 103 | 2017-06-14 | 2019-05-20 |
| A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia Sodium Zirconium Cyclosilicate (ZS) 10g, Sodium Zirconium Cyclosilicate (ZS) 5g, Placebo - Hyperkalemia | Phase 3 | Completed | AstraZeneca | 267 | 2017-03-03 | 2020-08-19 |
| Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Sodium zirconium cyclosilicate - Sodium Zirconium Cyclosilicate, Hyperkalemia | Phase 3 | Completed | Guangdong Provincial People's Hospital | 62 | 2016-11-01 | 2022-05-19 |
| Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months Sodium Zirconium Cyclosilicate - Hyperkalemia | Phase 3 | Completed | ZS Pharma, Inc. | 751 | 2014-06-30 | 2018-06-27 |
| Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. Sodium Zirconium Cyclosilicate - Hyperkalemia | Phase 3 | Completed | ZS Pharma, Inc. | 123 | 2014-05-31 | 2018-08-15 |
| Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. Sodium zirconium cyclosilicate, Placebo - Hyperkalemia | Phase 3 | Completed | ZS Pharma, Inc. | 258 | 2014-03-31 | 2018-12-07 |
| A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Patiromer, Placebo - Chronic Kidney Disease (CKD), Hyperkalemia (HK) | Phase 3 | Completed | Relypsa, Inc. | 243 | 2013-02-01 | 2021-06-03 |
| Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase) - Hyperkalemia | Phase 3 | Completed | ZS Pharma, Inc. | 754 | 2012-11-30 | 2018-10-12 |
Renal Insufficiency, Chronic (4) · Acute Kidney Injury (1) · Heart Failure (1) · Hyperparathyroidism, Secondary (1) · Hypertension (1) · Pseudohypoaldosteronism (1)
Metabolic Diseases (16) · Nutritional and Metabolic Diseases (16) · Water-Electrolyte Imbalance (16) · Chronic Disease (4) · Disease Attributes (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Renal Insufficiency (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Cardiovascular Diseases (1)
sodium zirconium cyclosilicate (10) · Suspensions (2) · patiromer (2) · zircon (2) · Calcium (1) · Streptozocin (1)
AstraZeneca (6) · ZS Pharma, Inc. (4) · Guangdong Provincial People's Hospital (1) · Relypsa, Inc. (1) · St George's, University of London (1) · Vifor Fresenius Medical Care Renal Pharma (1) · Vifor Pharma, Inc. (1) · Zeria Pharmaceutical (1)
United States (7) · Japan (5) · Australia (4) · United Kingdom (4) · China (3) · Russia (3) · South Africa (3) · Czechia (2) · Georgia (2) · Germany (2) · Hungary (2) · Italy (2) · Netherlands (2) · Serbia (2) · Ukraine (2)
Henrik Rasmussen, MD, PhD (3) · Debasish Banerjee, MD FRCP (1) · Henrik Rasmussen, MD (1) · Julian Platon, MD, PhD (1) · Shuangxin Liu, Ph.D (1) · Steven Fishbane, MD (1) · Yusuke Tomioka (1) · Zhaohui Ni (1)
PMID 32588430, PMID 31791288, PMID 25402495, PMID 25415807, PMID 29728199, PMID 32030422, PMID 32779057, PMID 33098526, PMID 33608263, PMID 35135481, PMID 35900838, PMID 37385905, PMID 39112102, PMID 39159624, PMID 39340493, PMID 39969301, PMID 41957746
2017 (1), 2018 (1)